In the intricate world of pharmaceutical chemistry, the precise nature of intermediate compounds dictates the success of drug development and manufacturing. Clidinium Bromide, known by its CAS Number 3485-62-9, is a crucial pharmaceutical intermediate with a well-defined chemical profile. This article provides an in-depth look at its properties and its significance in the industry.

Clidinium Bromide is characterized as a white crystalline solid. Its molecular structure is represented by the formula C22H26BrNO3, and it has a molecular weight of 432.35 g/mol. These specific details are vital for quality assurance and process optimization in pharmaceutical synthesis. The compound's utility is rooted in its anticholinergic properties, which enable it to block the action of acetylcholine. This mechanism is particularly beneficial in its application as an antispasmodic agent.

The primary role of Clidinium Bromide in the pharmaceutical sector is as a raw material for creating APIs, most notably in antispasmodic medications. These drugs are often formulated to alleviate symptoms of gastrointestinal issues, such as Irritable Bowel Syndrome (IBS) and peptic ulcers. By helping to relax the muscles of the digestive tract and reduce the secretion of stomach acid, Clidinium Bromide contributes to symptom relief for patients suffering from these conditions.

The manufacturing of Clidinium Bromide requires strict adherence to quality standards, with a minimum purity of 97% being a common requirement. This ensures its suitability for pharmaceutical applications. The reliable sourcing of this Clidinium Bromide for IBS treatment is a critical consideration for pharmaceutical companies, as it directly impacts the quality and availability of the final medicinal products. The compound's consistent chemical properties and established synthesis pathways make it a dependable intermediate for the global pharmaceutical market.